A new study suggests a possible link between GLP-1 weight loss drugs like Ozempic and Mounjaro and vision problems, including sudden vision loss. Researchers are investigating whether these ...

Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be short-lived deal ...

While there are no studies documenting the number of physicians taking GLP-1s, a number of physicians told the Times that they've noticed many colleagues growing thinner and sharing similar eating ...

As Ozempic use rises, some patients report unexpected nasal symptoms, prompting researchers to investigate this new and unusual side effect.

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

GLP1RA mimic the GLP-1 hormone in the body that helps control insulin and blood glucose levels and promotes feelings of satiety. GLP-1 binds to GLP1R on cells in the brain and pancreas.

US bakery major Flowers Foods has blamed ongoing bread category weakness and changing consumer preferences for ...

Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on w ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...